Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus.

[1]  C. Kwoh,et al.  Co‐morbid medical and psychiatric illness and substance abuse in HCV‐infected and uninfected veterans , 2007 .

[2]  A. Butt,et al.  Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. , 2007, Journal of viral hepatitis.

[3]  C. Kwoh,et al.  Rate and predictors of treatment prescription for hepatitis C , 2006, Gut.

[4]  C. Kwoh,et al.  Rates and predictors of hepatitis C virus treatment in HCV–HIV‐coinfected subjects , 2006, Alimentary pharmacology & therapeutics.

[5]  J. Macías,et al.  Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes , 2005, Gut.

[6]  A. Justice,et al.  Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans , 2005, AIDS.

[7]  S. Daniel.  Chronic Hepatitis C Treatment Patterns in African American Patients: An Update , 2005, The American Journal of Gastroenterology.

[8]  A. Butt,et al.  Reasons for non‐treatment of hepatitis C in veterans in care , 2005, Journal of viral hepatitis.

[9]  F. Carrat,et al.  Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. , 2004, JAMA.

[10]  J. Montaner,et al.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.

[11]  P. Volberding,et al.  Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. , 2004, The New England journal of medicine.

[12]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[13]  M. Fine,et al.  Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data. , 2003, American journal of public health.

[14]  A. Butt.  Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. , 2003, The AIDS reader.

[15]  L. Rabeneck,et al.  Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[17]  L. Leape,et al.  Comparison of Use of Medications After Acute Myocardial Infarction in the Veterans Health Administration and Medicare , 2001, Circulation.

[18]  J. Janisse,et al.  African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians , 2001, Journal of viral hepatitis.

[19]  M. Shiffman,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.

[20]  J. Reichen,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.

[21]  C DeShazer,et al.  Racial differences in the treatment of early-stage lung cancer. , 2000, The New England journal of medicine.

[22]  oseph,et al.  PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS , 2000 .

[23]  R. Califf,et al.  Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter? , 1997, The New England journal of medicine.